Forward-looking statements can generally be identified by words such as “potential,”“can,”“will,”“plan,”“may,”“could,”“would,”“expect,”“anticipate,”“seek,”“look forward,”“believe,”“committed,”“investigational,”...
Novartis was the first to scale the availability of RLTs in the market across different cancer types with Pluvicto (lutetium Lu 177 vipivotide tetraxetan) and Lutathera (lutetium Lu 177 dotatate). The company’s early and late-stage pipeline has several programs in or entering the clinic, as ...
every week, we're adding more sites. We're getting more sites to actively order. We're getting further into community oncology which will set us up not only for Pluvicto, but our broader RLT pipeline over time.
看重核素肿瘤药物的巨大发展潜力,近年来Novartis也在核药市场积极布局。2017年,Novartis以 $3.9 Bn收购法国AAA公司,2018年以 $2.1 Bn收购Endocyte,基于此建立并拓展了放射性配体疗法平台(Radioligand Therapy,RLT)。目前,Novartis拥有多款核药上市产品和十余条研发管线,拥有2款上市产品:Pluvicto™、Lutathera(177Lu-DO...
“In the short time since founding the company, the team at Mariana Oncology has developed a leading radiopharmaceutical discovery platform and an innovative pipeline. Our strategy has centered on overcoming the unique challenges of end-to-end radiopharmaceutical R&D and ultimately, delivery ...
Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and validate next generation DDR targets to enhanceNovart...
In 2023, Novartis completed its transformation into a “pure-play” innovative medicines business. We have a clear focus onfour core therapeutic areas(cardiovascular-renal-metabolic, immunology, neuroscience and ...
including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; our performance on and ability to comply with environmental, social and governance measures and requiremen...
In 2023, Novartis completed its transformation into a “pure-play” innovative medicines business. We have a clear focus onfour core therapeutic areas(cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple significant in-market and pipeline assets in each of these areas,...
In the first half of the year, in addition to investing in our internal R&D engine, we also brought in external innovation via bolt-on M&A and BD&L deals, particularly to strengthen our pipeline in oncology, as well as our RLT platform. In terms of returning capital to shareholders, ...